Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment

Objective: to study the breast cancer phenotype (ER/PR, FOXA1, HER2, Ki67) and the dynamics of changes in these markers in the tumour before and after neoadjuvant chemotherapy (NAT), compare them with metastases in the regional lymph nodes (LN). Materials and methods. The subject of the study was a...

Description complète

Détails bibliographiques

Auteurs principaux:	V. O. Bashlyk, A. G. Kudaibergenova, A. S. Artemyeva, A. L. Muravtseva, V. S. Chirsky, T. Yu. Semiglazova, V. V. Klimenko, V. F. Semiglazov
Format:	Artigo
Langue:	Russo
Publié:	Remedium Group LLC 2018-07-01
Collection:	Медицинский совет
Sujets:	breast cancer neoadjuvant chemotherapy tumor immunophenotype
Accès en ligne:	https://www.med-sovet.pro/jour/article/view/2547
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!